Aratana Therapeutics Inc.

Pharmacy Market

Vivera Pharmaceuticals, Inc. | May 18, 2022

Vivera Biosciences, a division of Vivera Pharmaceuticals dedicated to the research and development of innovative medical technologies and pharmaceutical therapies, is pleased to announce its collaborative progress on a Cooperative Research and Development Agreement with the National Institute of Neurological Disorders and Stroke an Institute within the National Institutes of Health that aims to foster and advance cutting-edge neuroscience research to reduce the burden of neurological disease. Th...

Jazz Pharmaceuticals | September 09, 2020

Jazz Pharmaceuticals plc today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. Under the terms of the research collaboration agre...

Business Insights

IceCure Medical Ltd | August 30, 2022

IceCure Medical Ltd. developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction of Vietnam's Ministry of Health for the ProSense System and accessories. The application covers indications including benign and malignant breast tumors, benign and malignant lung tumors, benign ...

Pharmacy Market

Businesswire | June 26, 2023

Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. The USPTO issued U.S. Patent No. 11,679,117, covering the clinical dosing regimen administering ganaxolone for SE patients, including t...